Advances & Revolutions in Heart Failure (ARHF)

"The book includes 15 sections and 152 chapters. It focuses on every aspect of heart failure management with enormous information about advances in clinical approach, imaging including echocardiography and multimodality imaging, drug, mechanical and surgical interventions for better patient care. It has tremendous innovative and research potential of understanding advances and revolutions in heart failure."

Contents
SECTION 1: CLINICAL SPECTRUM
1. Heart Failure in Women: Decoding the Missing Link 3
Harshit Khare, Roopali Khanna
2. Prevention of Heart Failure: The Chopra–Levy Online Heart Protection Program 9
Rick Levy, Lisa Tatum
3. Salt Intake Thresholds: Ultralow versus Low Sodium Debate 13
AK Pancholia
4. Trivandrum Heart Failure Registry 18
Harikrishnan S, Sanjay G, Jeemon P
5. ACC/AHA/HFSA Guidelines Update in Heart Failure Pharmacotherapy 23
Shraddha Ranjan, Manish Bansal, Ravi R Kasliwal, HK Chopra
6. Clinical Guidelines for HFrEF: AHA, ACC and ESC 30
Tapan Sinha, Jayanta Sharma, Mrinal Kanti Das
7. Noise Pollution, Cardiovascular Disease, and Heart Failure 40
Chanchal Pal, HK Chopra
SECTION 2: DRUGS IN HEART FAILURE
Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure
8. Angiotensin Receptor–Neprilysin Inhibitor and Heart Failure: An Iconic Molecule of Century 49
HK Chopra, Chandrashekhar K Ponde, Viveka Kumar, Anu Grover
9. New ACC/AHA and HFSA Guidelines of Angiotensin Receptor–Neprilysin Inhibitor in
Heart Failure 66
Abhishek, Gurpreet Singh Wander
10. Top 10 Take-Home Messages from ACC/AHA and HFSA on
Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure 72
Satyendra Tewari, Ashish Kumar Singh, Ashvanee Kumar Sharma
11. 2023 American College of Cardiology Expert Consensus for Heart Failure with
Preserved Ejection Fraction in Clinical Context 77
Rajeev Gupta
12. Differentiation between Heart Failure with Preserved Ejection Fraction and
Heart Failure with Reduced Ejection Fraction 89
Sanjay Mittal, Aparajita Kumar
13. Mechanism of Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure 96
Harsh Wardhan, Ramanand P Sinha, Parth Mashru, Aditya Goyal
14. Reverse Cardiac Remodeling: Role of Angiotensin Receptor–Neprilysin Inhibitor 100
Chandrashekhar K Ponde, Kunal A Patankar
15. Angiotensin Receptor–Neprilysin Inhibitor Algorithm and Guideline-directed
Medical Therapy Management of Heart Failure with Preserved Ejection Fraction 108
Mohit D Gupta, Ghazi Muheeb, Girish MP
Contentsxxxii
Code: Del-590 Title: Advances and Revolution in Heart Failure Stage: 1st Proof
Name: Md Iqbal Author: HK Chopra Time/Date: 02:04 pm/13 Feb 24
16. ARNI Algorithm and GDMT Management of HFrEF 114
Subhasish Deb, Ranjit Kr Nath
17. Angiotensin Receptor–Neprilysin Inhibitors in Heart Failure: Outcome Data 118
Sunil Roy Thottuvelil, Venugopal Krishnan Nair
18. How Long to Use Angiotensin Receptor–Neprilysin Inhibitor Therapy in
Heart Failure: Evidence-based Data 123
Rupesh Agarwal, Girish MP, Mohit D Gupta
19. Efficacy and Safety of Angiotensin Receptor–Neprilysin Inhibitor in
Acute Myocardial Infarction: Current Status 128
Saumitra Ray, Srina Ray
20. Angiotensin Receptor–Neprilysin Inhibitor in Postmyocardial Infarction and Heart Failure 131
Viveka Kumar
21. Angiotensin Receptor–Neprilysin Inhibitor Postpercutaneous Coronary Intervention in
ST-elevation Myocardial Infarction to Prevent Heart Failure 134
Sameer Gupta, Purshotam Lal, Richa Aggarwal
22. Angiotensin Receptor–Neprilysin Inhibitor and Cardiac Arrhythmia in Heart Failure 138
Surendra Chutani, Arun Chutani, Jui Shah
23. Angiotensin Receptor–Neprilysin Inhibitor in Ischemic Cardiomyopathy: New Dimensions 141
HK Chopra, Shachi Kalyani, Viveka Kumar
24. Angiotensin Receptor–Neprilysin Inhibitor from Molecular Structure to
Clinical Application in Heart Failure 146
VK Katyal, Ashima Katyal, Bijender Singh
25. Angiotensin Receptor–Neprilysin Inhibitor for Doxorubicin-mediated
Cardiotoxicity and Heart Failure 152
Vansh Arora, Raajit Chanana
26. Renal Safety and Efficacy of Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure 155
Dinesh Khullar, Raghav Khullar, Deepak Kumar Panigrahi
27. Angiotensin Receptor–Neprilysin Inhibitor: “When, for Whom,
and How Long in Heart Failure?” 162
Brian Pinto, Surendra Poonia
28. Angiotensin Receptor–Neprilysin Inhibitor and Mineralocorticoid Receptor Antagonist
Combination in PARAGON-HF: Odd Couple or Dynamic Duo? 167
Vaibhav Bandil, Suman Bhandari
29. Role of the Angiotensin Receptor–Neprilysin Inhibitor and Sodium–Glucose
Cotransporter 2 Inhibitor in Women with Heart Failure 171
Mohan Bhargava, Ankit Kumar, Ashutosh Baheti
30. Angiotensin Receptor–Neprilysin Inhibitor Improves Sexual Functions and
Fibrosis of the Clitoral and Vaginal Tissues in Females with Heart Failure 180
Deepak K Jumani
31. Is It Time to Adopt Angiotensin Receptor–Neprilysin Inhibitor Therapy as
Standard Care for Management of Hypertension? 184
Neelesh Pandey, Neeraj Pandit
32. Role of Angiotensin Receptor Blocker and Neprilysin Inhibitor in Resistant Hypertension 191
Lokre A, Dayasagar Rao V
33. Will ARNI Replace ARBs/ACEI in Hypertension to Heart Failure? 197
Jabir Abdullakutty, Vijin Joseph
Contents xxxiii
Code: Del-590 Title: Advances and Revolution in Heart Failure Stage: 1st Proof
Name: Md Iqbal Author: HK Chopra Time/Date: 02:04 pm/13 Feb 24
34. Role of Angiotensin Receptor–Neprilysin Inhibitor in Septic Cardiomyopathy 201
SN Pathak, Deeptanshu Jain, Pradeep Jain
35. Role of Angiotensin Receptor–Neprilysin Inhibitor in Takotsubo Cardiomyopathy 205
Rakesh Varma, Shekhar Kunal, Arvind Dambalkar
36. Role of Angiotensin Receptor–Neprilysin Inhibitor in Dilated Cardiomyopathy 211
Manbir Singh, Vivudh Pratap Singh
37. Role of Angiotensin Receptor–Neprilysin Inhibitor in Critical Care
Patients with Heart Failure 215
Aashish Jain, Manish Bansal, Yatin Mehta
38. Role of Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure Patients on Ventilator 220
Surabhi Awasthi, Kapil Dixit, Vikas Yadav, Anshika Chaturvedi Kashyap
39. Role of Angiotensin Receptor–Neprilysin Inhibitors in Heart Failure after
Heart Transplant Patients 227
Shobhit Saurav, Ratna Malika Kumar, Rajneesh Malhotra
40. Role of Angiotensin Receptor–Neprilysin Inhibitors in Patients with
Heart Failure on Pacemaker and Arrhythmias 231
Prashant T Upasani, Sameer Gupta, Purshotam Lal
41. MitraClip in Heart Failure in Patients on Angiotensin Receptor–Neprilysin Inhibitors:
When and How? 240
Ramesh Daggubati, Abdul Subhan Talpur, Mustafa Sajjad Cheema
42. Role of Angiotensin Receptor–Neprilysin Inhibitor in Pulmonary Arterial Hypertension
with Heart Failure 246
Arun K Chopra, Neha Chopra
43. Patiromer in Hyperkalemia in Heart Failure and Chronic Kidney Disease and
Angiotensin Receptor–Neprilysin Inhibitor Use 250
Kaushik Manna, Navanil Biswas, DP Sinha
44. Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure:
Pharmacodynamics and Outcome 255
Anil Pareek, Rujul Desai
Sodium–Glucose Cotransporter 2 Inhibitor in Heart Failure
45. New European Society of Cardiology Guidelines of Sodium–Glucose Cotransporter 2
Inhibitors in Heart Failure 263
Ashish Kumar Jain, JPS Sawhney, Simran Sawhney
46. Top Ten Trials of Sodium–Glucose Cotransporter 2 Inhibitors 268
Sanchita Sen, Olivia Mechanic, Christos Mihos, Deepika Misra
47. The Evolving Landscape: Integrating Sodium–Glucose Cotransporter 2 Inhibitors in
the Contemporary Management of Heart Failure 274
Saumitra Ray, HK Chopra, Sanjay Jain, Onkar C Swami
48. The Power and Promise of Sodium–Glucose Cotransporter 2 Inhibitor in Heart Failure with
Preserved Ejection Fraction 282
HK Chopra, Anu Grover, Viveka Kumar, Anil Pareek
49. Power and Promise of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with
Reduced Ejection Fraction: Outcome Data 290
Satyendra Tewari, Ashvanee Kumar Sharma, Ashish Kumar Singh
Contentsxxxiv
Code: Del-590 Title: Advances and Revolution in Heart Failure Stage: 1st Proof
Name: Md Iqbal Author: HK Chopra Time/Date: 02:04 pm/13 Feb 24
50. Clinical Outcome Data with Sodium–Glucose Cotransporter 2 Inhibitor in Heart Failure 297
Anil Dhall, Suman Jatain, Mahendra Chouhan, Jasneet Singh
51. Sodium–Glucose Cotransporter 2 Inhibitors in Acute Heart Failure 307
Maitreyee Bhattacharyya, Aditya Kapoor
52. Role of Sodium–Glucose Cotransporter 2 Inhibitors in Patients with
Diabetes Mellitus and Heart Failure 311
Vinod Mittal
53. Sodium–Glucose Cotransporter 2 Inhibitors in Pulmonary Hypertension in Heart Failure 317
Bhagwan Mantri, Ritesh Sharma, Tanymol
54. Indication, Contraindication, and Uniqueness of Sodium–Glucose Cotransporter 2
Inhibitor in Heart Failure 321
HK Chopra, Md Inamul Haque, Sunil M Raheja
55. Role of Sodium–Glucose Cotransporter 2 Inhibitor in Dilated Cardiomyopathy with
Heart Failure 330
Saubhik Kanjilal, Arup Dasbiswas
56. Role of Sodium–Glucose Cotransporter 2 Inhibitors in
Hypertrophic Obstructive Cardiomyopathy with Heart Failure 337
Sumit Rakshit, Debabrata Roy
57. Early Initiation of Sodium–Glucose Cotransporter 2 Inhibitor is
Important Irrespective of Ejection Fraction 340
Kajal Ganguly, Sandipta Roy, Mainak Mukhopadhyay
58. Role of Sodium–Glucose Transport Protein 2 Inhibitors in Septic Cardiomyopathy 343
Gaurav Kochhar, Yatin Mehta
59. Role of Sodium–Glucose Cotransporter 2 Inhibitors in Takotsubo Syndrome-inflicted
Cardiomyopathy 347
Sarita Gulati, Chaitanya Gulati
60. Sodium–Glucose Cotransporter 2 Inhibitors in Rheumatic Heart Disease with Heart Failure 355
Arati Dave Lalchandani
61. Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with
Preserved Ejection Fraction: Fighting the Enemy with a Newly Crafted Weapon 357
Harshit Khare, Aditya Kapoor
62. Role of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Atrial Fibrillation 360
Shraddha Ranjan, Kartikeya Bhargava
63. Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Atrial Fibrillation with
Stroke, Peripheral Vascular Disease 364
NN Khanna, Sushant Mishra, Swati Singh
64. Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Stroke and Atrial Fibrillation in
Diabetes Mellitus 369
Vitull K Gupta, Preeti Singh Dhoat, Meghna Gupta, Varun Gupta
65. Sodium–Glucose Cotransporter 2 Inhibitors (A Tale of Salt, Sugar, and Cancer):
Mortality and Morbidity Benefits in Heart Failure with Cancer 373
Indu Bansal Aggarwal, Hemant Madan, Harmesh Aggarwal
66. Role of Impella in Patients with Shock and Heart Failure 379
Sarita Rao, Roshan Rao, Kamlesh Kothawade, Achukatla Kumar
Contents xxxv
Code: Del-590 Title: Advances and Revolution in Heart Failure Stage: 1st Proof
Name: Md Iqbal Author: HK Chopra Time/Date: 02:04 pm/13 Feb 24
67. Dapagliflozin in Heart Failure with Preserved Ejection Fraction 386
Mohit Jindal, Ankit Tandon, Rohit Tandon
68. Role of Sodium–Glucose Cotransporter 2 Inhibitor in All Spectrums of Heart Failure 389
Dev Pahlajani, Pradeep Hasija
69. Mortality and Morbidity Benefits of Sodium–Glucose Cotransporter 2 Inhibitors 397
Sunil Modi, Ranjan Modi
70. Sodium–Glucose Cotransporter 2 Inhibitors in Worsening Heart Failure 401
AK Pancholia
71. Sodium–Glucose Cotransporter 2 Inhibitor in Heart Failure with Diabetes and
Chronic Kidney Disease 407
Sarita Bajaj, Yashaswi Pathak, Lekharaj Choudhary
72. Sodium–Glucose Cotransporter 2 Inhibitors in Chronic Kidney Disease and
Congestive Cardiac Failure 411
Sunil Prakash, Prabin K Majhi
73. Left Atrial Failure: The Role of SGLT2is, ARNI, Bisoprolol, and MRAs 418
Harinder K Bali, Navdeep S Sidhu
74. Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and
Mortality in Diabetes Mellitus 424
Namrata Gaur, Dushyant Singh Gaur
75. Cardiovascular Outcome Trials with Sodium–Glucose Cotransporter 2 Inhibitors in Diabetes 431
Rajeev Chawla, Shalini Jaggi, Siddhant Trehan
76. Development of Treatment Selection Algorithm for Sodium–Glucose Cotransporter 2
Inhibitors in Heart Failure 436
Devesh Kumar, Nirmal Ghati
77. Role of Sodium–Glucose Cotransporter 2 Inhibitors in Cardiac Remodeling:
Beyond Glycemic Control 440
Chandrashekhar K Ponde, Mohit Singhal
78. Vascular Remodeling Reversal and Improvement of Endothelial Dysfunction by
Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure 444
Shishu Shankar Mishra, Biswaranjan Mishra
79. Dipeptidyl Peptidase 4 Inhibitors and Cardiovascular Outcome [Heart Failure (HF)]:
From Bench to Bedside 450
HK Chopra, Chandrashekhar K Ponde, AK Pancholia, Jignesh Ved
Beta-blockers in Heart Failure
80. Bisoprolol Outcome Data in Hypertension to Heart Failure 456
Deepa Malik, JPS Sawhney, Ayush Kumar
81. American College of Cardiology/American Heart Association Guidelines on
Beta-blocker Use in Heart Failure 463
Vineet Bhatia, Meetu Arora, Upendra Kaul
82. Promise of Bisoprolol in Heart Failure: Present Status 467
Ajay Kumar Sinha, Shraddha Ranjan, Sushil Kumar, Pawan Kumar Singh, Shreyash Trived,
Deepashree, Manish Singh
83. Bisoprolol in Resistant Hypertension with Heart Failure: A Rising Star and not an Illusion 474
HK Chopra, Anu Grover, AK Pancholia, Anil Pareek
Contentsxxxvi
Code: Del-590 Title: Advances and Revolution in Heart Failure Stage: 1st Proof
Name: Md Iqbal Author: HK Chopra Time/Date: 02:04 pm/13 Feb 24
84. Uniqueness of Bisoprolol in Heart Failure 482
HK Chopra, Chandrashekhar K Ponde, Anu Grover, NR Shastry
85. Role of Bisoprolol in Chronic Kidney Disease with Heart Failure 491
Himanshu Verma, Sourabh Sharma
86. Role of Bisoprolol in Heart Failure with Stroke and Hypertension 498
Pradeep Jain, Deeptanshu Jain, SN Pathak
87. Uniqueness of Beta Blockers in Heart Failure 501
Komal Dahiya, Rajiv Passey
88. Morbidity and Mortality Benefits of Bisoprolol in Heart Failure 506
Dhiman Kahali, Asit Das, Sreya Mazumder
89. Role of Bisoprolol in Heart Failure with Diabetes Mellitus 514
Vinod Mittal
90. Role of Bisoprolol in Severe Mitral Regurgitation and Heart Failure 518
SB Gupta
91. Bisoprolol in Hypertension to Heart Failure 523
SN Narasingan, Aravind Duruvasal
92. Role of Bisoprolol’s Survival Benefits in Heart Failure 528
Ameet G Sattur
93. Bisoprolol in Atrial Fibrillation and Heart Failure with Reduced Ejection Fraction 532
Rohit Walia, Mohit Walia, Deepanshu Dhiman
94. Role of Bisoprolol in Tachyarrhythmia with Heart Failure 536
Jostol Pinto, A George Koshy
95. Role of Bisoprolol in Heart Failure Postmyocardial Infarction 540
Purneshwar Kumar Pandey, Mitendra Singh Yadav
96. Bisoprolol in Heart Failure due to COVID, Septic, and Peripartum Cardiomyopathy 545
Meera R, Vijayaraghavan G
97. The Role of Bisoprolol in Primary, Secondary, and Tertiary Prevention of
Sudden Cardiac Death in Heart Failure 550
Kiron Varghese
98. Reverse Cardiac Remodeling: Role of Beta-blockers 554
Chandrashekhar K Ponde, Kunal A Patankar
99. Beta Blockers in the Management of Chronic Heart Failure 558
M Somasundaram, GV Senthilnathan, R Divya
100. Use of Beta-blockers in Patients with Heart Failure and Comorbidities 562
I Sathyamurthy, KN Srinivasan
101. Beyond Beats: Deciphering Bisoprolol in Heart Failure Care 566
Tiny Nair, HK Chopra, Sanjay Jain, Onkar C Swami
Ferric Carboxymaltose and Heart Failure
102. Ferric Carboxymaltose: A Fifth Pillar in Heart Failure Management 575
Aniruddha De
103. European Society of Cardiology Recommendation for Ferric Carboxymaltose
in Heart Failure 582
Satyanarayan Routray, Nirmal Kumar Mohanty, Siddhartha Pandey
Contents xxxvii
Code: Del-590 Title: Advances and Revolution in Heart Failure Stage: 1st Proof
Name: Md Iqbal Author: HK Chopra Time/Date: 02:04 pm/13 Feb 24
104. Ferric Carboxymaltose in Heart Failure with Kidney Disease 585
Dilip Bhalla, Ramesh Kumar Sah, Retesh Kumar Singh
105. Global Data on Ferric Carboxymaltose in Heart Failure 590
Prabhakar Dorairaj, Adhiti Krishnamoorthy
106. Iron Deficiency and Heart Failure: Current Perspective 595
Saumitra Ray, Srina Ray
107. Navigating Heart Failure: Unraveling the Role of Ferric Carboxymaltose in
Comprehensive Patient Care 599
HK Chopra, Heena Bhojwani, Sanjay Jain, Onkar C Swami
Mineralocorticoid Receptor Antagonists and Heart Failure
108. Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction
and Heart Failure with Preserved Ejection Fraction 610
VV Muthusamy, Dhanvanth Rajesh B, Anand Priya VVM, LN Meena
109. Mineralocorticoid Receptor Antagonists in HFrEF: ACC/AHA Guidelines 615
Abhishek, Nikita Sharma, Gurpreet Singh Wander
110. Mineralocorticoid Receptor Antagonists in Heart Failure with
Reduced Ejection Fraction: Outcome Data 620
Rajan Joseph Manjuran
Vericiguat and Heart Failure
111. Vericiguat in Heart Failure: What are the Guidelines? 622
SS Iyengar, Sneha Karekar
112. Vericiguat in Heart Failure 627
J Cecily Mary Majella, Geetha Subramanian, Surendran
113. Vericiguat in Heart Failure: Scientific Evidence to Clinical Practice 631
Vishal Rastogi, Pragya Kumari, Vijay Kumar
114. Worsening Heart Failure: Identifying the Patient Who will Benefit with Vericiguat 638
Vidyut Jain, Avani Jain
SECTION 3: DIAGNOSTIC BIOMARKERS
115. Role of N‐terminal Fragment of pro-B-type Natriuretic Peptide: Diagnostic, Prognostic,
and Therapeutic Implications 647
Srikanta Sharma, Aayushi Gupta, Lalatendu Mohanty, HK Chopra
SECTION 4: ECHO, IMAGING AND HEART FAILURE
116. Effect of Angiotensin Receptor–Neprilysin Inhibitors on Left Ventricular and
Left Atrial Strain in Heart Failure 655
Donovon Allen, Srijani Thannir, Navin C Nanda, HK Chopra
117. Echocardiographic Reverse Remodeling with Angiotensin Receptor–Neprilysin Inhibitor in
Heart Failure 660
Shivani Priyadarshni, Aiham Albaeni, Masood Ahmad
118. Echocardiographic-guided Therapy in Heart Failure 665
Dennis Fong, Iniya Rajendran, Rajesh Janardhanan
Contentsxxxviii
Code: Del-590 Title: Advances and Revolution in Heart Failure Stage: 1st Proof
Name: Md Iqbal Author: HK Chopra Time/Date: 02:04 pm/13 Feb 24
119. Effect of E/e’ in Heart Failure Patients on Angiotensin Receptor–Neprilysin
Inhibitor Therapy 674
Naveen Garg, KK Kapur
120. Impact of Sodium–Glucose Cotransporter 2 Inhibitor on E/e’ in Patients with
Heart Failure 680
Naveen Garg, KK Kapur
121. Echocardiographic Assessment of Left Ventricular Hypertrophy and
Left Atrial Volume in Heart Failure 685
Manish Bansal, Ravi R Kasliwal, HK Chopra, Karishma Walia
122. Echocardiographic Evaluation of Heart Failure in Emergency 694
Rekha Mishra, Uday S Yadav, Amitabh Poonia
123. Echocardiography Evaluation of the Left Atrial Strain on Patients with
SGLT2 Inhibitors with Heart Failure 707
Amrish Agrawal, Thair Al Jumaily, Vishal Agrawal, Tarik Salim
124. Effect of Sodium–Glucose Cotransporter 2 Inhibitors on
Increased Left Atrial Stiffness Index in Heart Failure 712
Pritam Kitey, Mohit Bhagwati, Rahul Mehrotra, Amitabh Yaduvanshi, Vikas Kataria, Shivank Gupta
125. Heart Failure in Hypertrophic Cardiomyopathy Mechanisms and Management 718
S Shanmugasundaram, U Ilayaraja, BG Vinodkumar
126. Echocardiographic Variables on Cardiac Remodeling Reversal by
Bisoprolol in Heart Failure 734
Ankush Sachdeva, Sanil Omar, Ashok Kumar Omar
127. Echocardiographic Evaluation of Right Ventricular Parameters in Heart Failure—
On ARNI and SGLT2i 739
Satish C Govind
128. Cardiac Magnetic Resonance Imaging Evaluation on Cardiac Remodeling Reversal after
Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure 745
Priya Jagia, Damandeep Singh
129. Cardiac Magnetic Resonance Evaluation on Cardiac Remodeling Reversal after
Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure 753
Mona Bhatia, Parveen Kumar, Prasit Maity, Amit Garg, Karthika Gopal, Sachin Raiya, Akash
130. Role of Computed Tomography Evaluation for Transcatheter Aortic Valve Implantation 757
Anshika Gulati, Parveen Gulati
131. Angiotensin Receptor–Neprilysin Inhibitor and Extracorporeal Membrane Oxygenation 763
Poonam Malhotra Kapoor
132. Sodium–Glucose Cotransporter 2 Inhibitor and Extracorporeal Membrane Oxygenation
in Heart Failure 770
Poonam Malhotra Kapoor
SECTION 5: CARDIAC RESYNCHRONIZATION THERAPY AND DEVICE
133. Does Angiotensin Receptor–Neprilysin Inhibitor Postpone the Need of Device Therapy in
Heart Failure with Reduced Ejection Fraction? 779
Viveka Kumar
Contents xxxix
Code: Del-590 Title: Advances and Revolution in Heart Failure Stage: 1st Proof
Name: Md Iqbal Author: HK Chopra Time/Date: 02:04 pm/13 Feb 24
SECTION 6: CORONARY ARTERY DISEASE AND HEART FAILURE
134. Acute Coronary Syndromes and Heart Failure 783
Brian Pinto, Bhavik Dhirawani, Neeraj A Desai
135. Role of Sodium–Glucose Cotransporter 2 Inhibitors Post-CABG with Heart Failure 789
Anirban Kundu, OP Yadava
SECTION 7: STROKE AND HEART FAILURE
136. Sodium–Glucose Cotransporter 2 Inhibitors in Stroke Prevention 797
Vinit Suri, Kunal Suri, Kanika Suri
137. Role of Angiotensin Receptor–Neprilysin Inhibitors in Stroke 803
Vaibhav Deorari, Mukesh Kumar, Nilesh Jadhao, Joy Dev Mukherji
SECTION 8: ARRHYTHMIA AND HEART FAILURE
138. Newer Left Ventricular Assist Devices: Current Scenario 811
G Justin Paul, J Cecily Mary Majella
139. Review Outcomes of Recent Device Trials in Heart Failure 820
Aparna Jaswal, Wasim Rashid
SECTION 9: HYPERTENSION
140. Hypertension and Heart Failure as Stroke Risk Factors 827
Pawan K Sharma, HK Chopra
141. Heart Failure and Hypertension 833
Jostol Pinto, A George Koshy
SECTION 10: VALVULAR
142. Heart Support Devices in Heart Failure 841
Vivudh Pratap Singh, Vishal Rastogi, Vijay Kumar, Ashok Seth
SECTION 11: CONGENITAL HEART DISEASE AND HEART FAILURE
143. Heart Failure in Pediatric Group 853
Hala Elmarsafawy, Shimaa Khaled
144. End-stage Congestive Heart Failure between the Present and the Future:
Is there a Pharmaceutical way to get around it? 865
Sonia El Saeidi, Antoine Abdel Massih
145. Sodium–Glucose Cotransporter 2 Inhibitors in Pediatric Heart Failure:
A Promising Adjuvant/Guidelines 868
IB Vijayalakshmi, Akkatai S Teli
Contentsxl
Code: Del-590 Title: Advances and Revolution in Heart Failure Stage: 1st Proof
Name: Md Iqbal Author: HK Chopra Time/Date: 02:04 pm/13 Feb 24
SECTION 12: NUTRITIONAL
146. Coenzyme Q10 Deficiency and Heart Failure 873
Pawan K Sharma, HK Chopra
147. Evolving Scenario of Edible Oils in India: A Scientific Perspective on their
Prospective Role in the Management of Noncommunicable Diseases 879
Shashank Joshi, Shilpa Vora
SECTION 13: HEART FAILURE AND CARDIO-ONCOLOGY
148. Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure with Cancer Patients 891
Kanika Sharma Sood, Mohit Rana, Aditi Tanwar
149. Echocardiography Evaluation of Heart Failure in Oncology 894
Madhu Mary Minz, Manish Bansal, Ravi R Kasliwal, HK Chopra
SECTION 14: REHABILITATION
150. Exercise Protocol in HFrEF on ARNI, SGLT2i, MRA, and Bisoprolol 907
Chetan P Shah, Charan Reddy KV
151. Role of Yoga in Heart Failure 912
SC Manchanda, Ashish Kumar Jain, Kushal Madan
SECTION 15: ARTIFICIAL INTELLIGENCE
152. Artificial Intelligence: Its Impact in the Management of Heart Failure 919
Vidur Mahajan, Vasanthakumar Venugopal